Question 86

Therapeutic duplication is a concern for the patient.

Therapeutic duplication occurs when a patient is prescribed multiple medications that serve similar purposes or have overlapping therapeutic effects. In this case, both verapamil and nifedipine are calcium channel blockers used to treat hypertension and other cardiac conditions, making their concurrent use a significant concern.

A) Drug-disease contraindication

Drug-disease contraindications refer to situations where a medication may exacerbate an existing condition. While both verapamil and nifedipine can interact with certain diseases, the primary concern in this case is not a specific disease contraindication but rather the overlap in therapeutic effects.

B) Narrow therapeutic index

A narrow therapeutic index indicates that there is a small margin between the effective dose and the toxic dose of a drug. While both medications can have specific dosing considerations, this does not apply directly to the concern of therapeutic duplication presented in this scenario.

C) Duration of therapy

Duration of therapy refers to how long a medication should be prescribed for a patient. This option does not pertain to the specific issue of overlapping medication effects seen with both verapamil and nifedipine, as both can be used long-term under management.

D) Therapeutic duplication

Therapeutic duplication occurs when two medications with similar mechanisms or effects are prescribed simultaneously, which may increase the risk of side effects or adverse reactions. In this case, both verapamil and nifedipine are calcium channel blockers, leading to potential duplication of therapeutic effects and heightened risk for the patient.

Conclusion

The correct answer, therapeutic duplication, highlights a critical concern when a patient is prescribed verapamil and nifedipine together, as both medications perform similar functions in managing cardiovascular issues. Other options, such as drug-disease contraindications, narrow therapeutic index, and duration of therapy, do not directly address the issue of overlapping treatment strategies, reinforcing why therapeutic duplication is the primary concern in this scenario.